Inventor · disambiguated record
Jörg Willuda
Also filed as: WILLUDA JOERG · WILLUDA JORG · Willuda Jörg
10 granted patents·12 pending applications·109 citations·filing 2001–2022
89Inventor score
Files withSEATTLE GENETICS INC4LERCHEN HANS-GEORG3BAYER AG2Bayer Pharma AG2DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS2
Top patents by PatentIndex Score
22 records- 0193US7129254B2Effector conjugates, process for their production and their pharmaceutical useSCHERING AG·Filed 2003·Granted Oct 31, 2006·51 cites·15 claims
- 0292US8992932B2Binder-drug conjugates (ADCs) and use thereofSEATTLE GENETICS INC·Filed 2012·Granted Mar 31, 2015·26 cites·12 claims
- 0385US10584167B2Anti-CEACAM6 antibodies and uses thereofBayer Pharma AG·Filed 2016·Granted Mar 10, 2020·4 cites·16 claims
- 0483US7335775B2Effector conjugates, process for their production and their pharmaceutical useSCHERING AG·Filed 2006·Granted Feb 26, 2008·5 cites·7 claims
- 0582US7858088B2Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragmentUNIV ZUERICH·Filed 2008·Granted Dec 28, 2010·4 cites·7 claims
- 0682US7033798B2Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragmentUNIV ZUERICH·Filed 2001·Granted Apr 25, 2006·14 cites·10 claims
- 0779US11866495B2Anti-CEACAM6 antibodies and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2020·Granted Jan 9, 2024·1 cites·20 claims
- 0874US8137932B2Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragmentPLUECKTHUN ANDREAS·Filed 2010·Granted Mar 20, 2012·4 cites·16 claims
- 0961US11773164B2Anti-CEACAM6 antibodies and uses thereofBayer Pharma AG·Filed 2020·Granted Oct 3, 2023·0 cites·20 claims
- 1061US2015030618A1Novel binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2014·Application pending·0 cites
- 1160US2008166362A1New effector conjugates, process for their production and their pharmaceutical useBERGER MARKUS·Filed 2007·Application pending·0 cites
- 1257US2014127240A1Novel Binder-Drug Conjugates (ADCs) and Use of SameLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 1357US2013122024A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 1456US2013066055A1New binder-drug conjugates (adcs) and use thereofLERCHEN HANS-GEORG·Filed 2012·Application pending·0 cites
- 1556US2016193359A1New binder-drug conjugates (adcs) and use thereofSEATTLE GENETICS INC·Filed 2016·Application pending·0 cites
- 1654US2015246136A1NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAMESEATTLE GENETICS INC·Filed 2015·Application pending·0 cites
- 1754US2024368280A1Anti-cecam6 antibodies with reduced side-effectsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2022·Application pending·0 cites
- 1851US2017158775A1Anti-c4.4a antibodies and uses thereofBAYER IP GMBH·Filed 2017·Application pending·0 cites
- 1950US12221479B2Pharmaceutical combination of anti CEACAM6 and TIM3 antibodiesBAYER AG·Filed 2019·Granted Feb 11, 2025·0 cites·11 claims
- 2046US2009137002A1Anti ephb4 antibodies and antibody fragmentsPETRUL HEIKE·Filed 2008·Application pending·0 cites
- 2145US2022010017A1Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancerBAYER AG·Filed 2019·Application pending·0 cites
- 2241US2012321619A1Anti-c4.4a antibodies and uses thereofLINDEN LARS·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jörg Willuda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →